Pembrolizumab in Refractory Advanced Esophageal Cancer
Status:
Active, not recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy as a possible treatment for advanced
esophageal cancer.
The study intervention involved in this study is:
-Pembrolizumab